Detailed answers about LIAN XINGOVERSEAS MEDICINE CO., LTD., including incorporation, status, business activity, and accounts information.
When was LIAN XINGOVERSEAS MEDICINE CO., LTD. founded?
LIAN XINGOVERSEAS MEDICINE CO., LTD. was officially incorporated on 5 February 2025 and is registered under company number 16232312. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is LIAN XINGOVERSEAS MEDICINE CO., LTD.?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of LIAN XINGOVERSEAS MEDICINE CO., LTD.?
LIAN XINGOVERSEAS MEDICINE CO., LTD.'s current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does LIAN XINGOVERSEAS MEDICINE CO., LTD. do?
LIAN XINGOVERSEAS MEDICINE CO., LTD. operates in the following sectors: 46180 - Agents specialized in the sale of other particular products, 46460 - Wholesale of pharmaceutical goods, 47910 - Retail sale via mail order houses or via Internet, 63120 - Web portals. These SIC codes provide insight into the company's business activities and industry focus.
What is LIAN XINGOVERSEAS MEDICINE CO., LTD.'s registered address?
The registered office address of LIAN XINGOVERSEAS MEDICINE CO., LTD. is 37 CROYDON ROAD, BECKENHAM, UNITED KINGDOM, BR3 4AB. This is the official address filed with Companies House for legal and statutory correspondence.
Is LIAN XINGOVERSEAS MEDICINE CO., LTD. financially stable?
Financial accounts for LIAN XINGOVERSEAS MEDICINE CO., LTD. are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.